Brought to you by

Octapharma gets recombinant technology, minority stake in Glycotope
20 Oct 2015
Executive Summary
Glycotope GMBH licensed Octapharma AG exclusive global rights to its recombinant technology GlycoExpress (GEX) cell line plus research, development, and commercialization rights to its preclinical Factor VII GEX blood coagulant candidates for hemophilia.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com